Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration

SHANGHAI and BOSTON, July 3, 2023 -- (Healthcare Sales & Marketing Network) -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, today announced that the U.S. F... Regenerative Medicine, Ophthalmology, FDA Skyline Therapeutics, macular degeneration, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news